Non-epileptic pedaling-like movement induced by triclofos

Akihisa Okumura1, Toru Kato, Fumio Hayakawa

  • 1Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan. okumura@med.nagoya-u.ac.jp

Brain & Development
|September 8, 2004
PubMed

Insights

Triclofos sedation in an infant caused non-epileptic, pedaling-like movements. These movements, resembling leg pedaling, were temporary and not indicative of seizures.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Sedation is crucial for pediatric imaging procedures like computed tomography (CT).
  • Triclofos is a sedative agent used in pediatric care.
  • Adverse drug reactions in infants require careful monitoring and documentation.

Observation:

  • An infant received 80 mg/kg of triclofos for sedation during a head CT scan.
  • Within 15 minutes, the infant exhibited unusual pedaling-like movements and slight upward eye deviation.
  • The movements could be manually stopped and occurred intermittently for approximately 2 hours.

Findings:

  • Electroencephalography (EEG) during the movements showed physiological semirhythmic theta waves.
  • No epileptiform discharges or paroxysmal activities were observed on the EEG.
  • The observed movements were characterized as non-epileptic.

Implications:

  • This case highlights a potential, transient side effect of triclofos in infants.
  • Distinguishing drug-induced movements from seizures is critical in pediatric neurology.
  • Further investigation into the neurophysiological effects of triclofos in pediatric populations may be warranted.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: